Invivyd, Inc.

NasdaqGM IVVD

Invivyd, Inc. Free Cash Flow Yield on February 06, 2025: -81.18%

Invivyd, Inc. Free Cash Flow Yield is -81.18% on February 06, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Invivyd, Inc. 52-week high Free Cash Flow Yield is -76.18% on February 05, 2025, which is 6.16% above the current Free Cash Flow Yield.
Invivyd, Inc. 52-week low Free Cash Flow Yield is -449.36% on January 31, 2025, which is -453.54% below the current Free Cash Flow Yield.
Invivyd, Inc. average Free Cash Flow Yield for the last 52 weeks is -314.56%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGM: IVVD

Invivyd, Inc.

CEO	Dr. Robert D. Allen Ph.D.
IPO Date	Aug. 6, 2021
Location	United States
Headquarters	1601 Trapelo Road
Employees	94
Sector	Healthcare
Industries Vaccines Biotechnology Clinical Trials Pharmaceuticals

Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Key trends

Past 5 years